How to buy BioSpecifics Technologies stock

BioSpecifics Technologies Corp is a biotechnology business based in the US. BioSpecifics Technologies shares (BSTC) are listed on the PINK and all prices are listed in US Dollars. BioSpecifics Technologies employs 7 staff and has a trailing 12-month revenue of around 0.00.

BioSpecifics Technologies share price

Use our graph to track the performance of BSTC stocks over time.

BioSpecifics Technologies shares at a glance

• Key figures

Information last updated 2021-01-11.

52-week range	$51.03 - $88.80
50-day moving average	$88.50
200-day moving average	$70.09
Wall St. target price	$88.50
PE ratio	37.5127
Dividend yield	N/A (0%)
Earnings per share (TTM)	$2.36

Buy BioSpecifics Technologies shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is BioSpecifics Technologies under- or over-valued?

Valuing BioSpecifics Technologies stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioSpecifics Technologies's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

BioSpecifics Technologies's P/E ratio

BioSpecifics Technologies's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 38x. In other words, BioSpecifics Technologies shares trade at around 38x recent earnings.

BioSpecifics Technologies's PEG ratio

BioSpecifics Technologies's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.36. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioSpecifics Technologies's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

BioSpecifics Technologies's EBITDA

BioSpecifics Technologies's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $23.6 million.

The EBITDA is a measure of a BioSpecifics Technologies's overall financial performance and is widely used to measure a its profitability.

BioSpecifics Technologies financials

Revenue TTM	$36.6 million
Operating margin TTM	64.76%
Gross profit TTM	$38.2 million
Return on assets TTM	11.58%
Return on equity TTM	0%
Profit margin	47.43%
Book value	$18.42
Market capitalisation	$650.2 million

TTM: trailing 12 months

Shorting BioSpecifics Technologies shares

There are currently 74,067 BioSpecifics Technologies shares held short by investors – that's known as BioSpecifics Technologies's "short interest". This figure is 22.5% up from 60,464 last month.

There are a few different ways that this level of interest in shorting BioSpecifics Technologies shares can be evaluated.

BioSpecifics Technologies's "short interest ratio" (SIR)

BioSpecifics Technologies's "short interest ratio" (SIR) is the quantity of BioSpecifics Technologies shares currently shorted divided by the average quantity of BioSpecifics Technologies shares traded daily (recently around 217844.11764706). BioSpecifics Technologies's SIR currently stands at 0.34. In other words for every 100,000 BioSpecifics Technologies shares traded daily on the market, roughly 340 shares are currently held short.

However BioSpecifics Technologies's short interest can also be evaluated against the total number of BioSpecifics Technologies shares, or, against the total number of tradable BioSpecifics Technologies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioSpecifics Technologies's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 BioSpecifics Technologies shares in existence, roughly 10 shares are currently held short) or 0.0119% of the tradable shares (for every 100,000 tradable BioSpecifics Technologies shares, roughly 12 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BioSpecifics Technologies.

Find out more about how you can short BioSpecifics Technologies stock.

BioSpecifics Technologies share dividends

We're not expecting BioSpecifics Technologies to pay a dividend over the next 12 months.

Have BioSpecifics Technologies's shares ever split?

BioSpecifics Technologies's shares were split on a 2:1 basis on 20 April 1992. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your BioSpecifics Technologies shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for BioSpecifics Technologies shares which in turn could have impacted BioSpecifics Technologies's share price.

BioSpecifics Technologies share price volatility

Over the last 12 months, BioSpecifics Technologies's shares have ranged in value from as little as $51.03 up to $88.8. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while BioSpecifics Technologies's is 0.2383. This would suggest that BioSpecifics Technologies's shares are less volatile than average (for this exchange).

BioSpecifics Technologies overview

BioSpecifics Technologies Corp. , a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.

Frequently asked questions

• What percentage of BioSpecifics Technologies is owned by insiders or institutions?

  Currently 18.641% of BioSpecifics Technologies shares are held by insiders and 66.477% by institutions.

• How many people work for BioSpecifics Technologies?

  Latest data suggests 7 work at BioSpecifics Technologies.

• When does the fiscal year end for BioSpecifics Technologies?

  BioSpecifics Technologies's fiscal year ends in December.

• Where is BioSpecifics Technologies based?

  BioSpecifics Technologies's address is: Delaware Corporate Center II, Wilmington, DE, United States, 19803

• What is BioSpecifics Technologies's ISIN number?

  BioSpecifics Technologies's international securities identification number is: US0909311062

• What is BioSpecifics Technologies's CUSIP number?

  BioSpecifics Technologies's Committee on Uniform Securities Identification Procedures number is: 090931106